Prueba del uso de fármacos en investigación atezolizumab y/o bevacizumab con o sin quimioterapia estándar en el tratamiento de segunda línea de cánceres de cabeza y cuello en estadio avanzado
Un ensayo de fase II/III de quimioterapia + cetuximab frente a quimioterapia + bevacizumab frente a atezolizumab + bevacizumab después de la progresión de la inhibición del punto de control inmunitario en cánceres de cabeza y cuello recurrentes/metastásicos
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
- Carcinoma de células escamosas de cabeza y cuello recidivante
- Carcinoma de células escamosas de hipofaringe recidivante
- Carcinoma de células escamosas de laringe recidivante
- Carcinoma de células escamosas de cabeza y cuello metastásico
- Carcinoma orofaríngeo mediado por VPH en estadio clínico IV (p16-positivo) AJCC v8
- Carcinoma de hipofaringe en estadio IV AJCC v8
- Cáncer de laringe en estadio IV AJCC v8
- Cáncer de labio y de cavidad oral en estadio IV AJCC v8
- Carcinoma orofaríngeo en estadio IV (p16-negativo) AJCC v8
- Carcinoma de células escamosas de hipofaringe metastásico
- Carcinoma de células escamosas de laringe metastásico
- Carcinoma metastásico de labio y cavidad oral
- Carcinoma metastásico de células escamosas de la cavidad nasal
- Carcinoma de células escamosas nasofaríngeo metastásico
- Carcinoma de células escamosas de faringe metastásico
- Carcinoma metastásico de células escamosas sinonasales
- Carcinoma de células escamosas de labio y cavidad oral recidivante
- Carcinoma de células escamosas de nasofaringe recidivante
- Carcinoma de células escamosas de faringe recidivante
- Carcinoma de células escamosas sinonasal recidivante
- Carcinoma nasofaríngeo en estadio IV AJCC v8
- Cáncer de seno nasal en estadio IV AJCC v8
- Carcinoma de células escamosas cutáneas de cabeza IV en etapa IV y cuello Carcinoma de células escamosas AJCC V8
Intervención / Tratamiento
Intervención / Tratamiento
- Droga: Carboplatin
- Biológico: Bevacizumab
- Droga: Cisplatin
- Droga: Docetaxel
- Procedimiento: Biospecimen Collection
- Procedimiento: Magnetic Resonance Imaging
- Procedimiento: Echocardiography Test
- Procedimiento: Computed Tomography
- Procedimiento: Positron Emission Tomography
- Biológico: Atezolizumab
- Biológico: Cetuximab
Descripción detallada
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin, California, Estados Unidos, 94568
- Epic Care-Dublin
-
Emeryville, California, Estados Unidos, 94608
- Epic Care Partners in Cancer Care
-
Irvine, California, Estados Unidos, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez, California, Estados Unidos, 94553-3156
- Contra Costa Regional Medical Center
-
Orange, California, Estados Unidos, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Estados Unidos, 94304
- VA Palo Alto Health Care System
-
Palo Alto, California, Estados Unidos, 94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby, Connecticut, Estados Unidos, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Estados Unidos, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Estados Unidos, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Estados Unidos, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Estados Unidos, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Estados Unidos, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
North Haven, Connecticut, Estados Unidos, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange, Connecticut, Estados Unidos, 06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford, Connecticut, Estados Unidos, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Estados Unidos, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Estados Unidos, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Estados Unidos, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Estados Unidos, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, Estados Unidos, 33316
- Broward Health Medical Center
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Estados Unidos, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Estados Unidos, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Estados Unidos, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Harvey, Illinois, Estados Unidos, 60426
- Ingalls Memorial Hospital
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Estados Unidos, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Estados Unidos, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Estados Unidos, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Yorkville, Illinois, Estados Unidos, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Estados Unidos, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Estados Unidos, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Estados Unidos, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Estados Unidos, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Estados Unidos, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland, Maryland, Estados Unidos, 21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
St Louis, Missouri, Estados Unidos, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Estados Unidos, 88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton, North Carolina, Estados Unidos, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Estados Unidos, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Steubenville, Ohio, Estados Unidos, 43952
- Trinity's Tony Teramana Cancer Center
-
Toledo, Ohio, Estados Unidos, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Estados Unidos, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Estados Unidos, 15009
- UPMC-Heritage Valley Health System Beaver
-
Butler, Pennsylvania, Estados Unidos, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill, Pennsylvania, Estados Unidos, 17011
- UPMC Camp Hill
-
Carlisle, Pennsylvania, Estados Unidos, 17015
- Carlisle Regional Cancer Center
-
Cranberry Township, Pennsylvania, Estados Unidos, 16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie, Pennsylvania, Estados Unidos, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Estados Unidos, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Estados Unidos, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg, Pennsylvania, Estados Unidos, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana, Pennsylvania, Estados Unidos, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, Estados Unidos, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Estados Unidos, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Estados Unidos, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Estados Unidos, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant, Pennsylvania, Estados Unidos, 15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon, Pennsylvania, Estados Unidos, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights, Pennsylvania, Estados Unidos, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, Estados Unidos, 16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15219
- UPMC-Mercy Hospital
-
Seneca, Pennsylvania, Estados Unidos, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- UPMC Cancer Center-Uniontown
-
Washington, Pennsylvania, Estados Unidos, 15301
- UPMC Cancer Center-Washington
-
West Mifflin, Pennsylvania, Estados Unidos, 15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport, Pennsylvania, Estados Unidos, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Estados Unidos, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Estados Unidos, 17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly, Rhode Island, Estados Unidos, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Estados Unidos, 37932
- Covenant Health Cancer Centers - West
-
Lenoir City, Tennessee, Estados Unidos, 37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge, Tennessee, Estados Unidos, 37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury, Vermont, Estados Unidos, 05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha, Wisconsin, Estados Unidos, 53188
- UW Cancer Center at ProHealth Care
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo blood sample collection
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo CT scan
Otros nombres:
Undergo PET scan
Otros nombres:
Given IV
Otros nombres:
|
|
Experimental: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo blood sample collection
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo CT scan
Otros nombres:
Undergo PET scan
Otros nombres:
|
|
Experimental: Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Otros nombres:
Undergo blood sample collection
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo CT scan
Otros nombres:
Undergo PET scan
Otros nombres:
Given IV
Otros nombres:
|
|
Experimental: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo blood sample collection
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo CT scan
Otros nombres:
Undergo PET scan
Otros nombres:
Given IV
Otros nombres:
|
|
Experimental: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo CT scan
Otros nombres:
Undergo PET scan
Otros nombres:
Given IV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia libre de progresión (PFS) (Fase II)
Periodo de tiempo: Tiempo desde el inicio del tratamiento hasta la progresión de la enfermedad o la muerte, evaluado hasta 5 años desde la aleatorización
|
Tiempo desde el inicio del tratamiento hasta la progresión de la enfermedad o la muerte, evaluado hasta 5 años desde la aleatorización
|
|
|
Overall survival (OS) (Phase III)
Periodo de tiempo: Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidencia de eventos adversos (Fase III)
Periodo de tiempo: Hasta 30 días después de finalizar el tratamiento
|
Hasta 30 días después de finalizar el tratamiento
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
Periodo de tiempo: Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
Periodo de tiempo: Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
Periodo de tiempo: Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
Periodo de tiempo: Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Aarti Bhatia, ECOG-ACRIN Cancer Research Group
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Neoplasias de las vías respiratorias
- Enfermedades Otorrinolaringológicas
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Enfermedades Nasofaríngeas
- Enfermedades faríngeas
- Carcinoma De Células Escamosas
- Enfermedades de la laringe
- Neoplasias Nasofaríngeas
- El carcinoma nasofaríngeo
- Carcinoma de células escamosas de cabeza y cuello
- Carcinoma
- Neoplasias Laríngeas
- Neoplasias de la Boca
- Neoplasias orofaríngeas
- Neoplasias Hipofaríngeas
- Neumonía intersticial linfoidea
- Aminoácidos, péptidos y proteínas
- Proteínas
- Compuestos de azufre
- Químicos orgánicos
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Elementos
- Rieles
- Técnicas de química, analítica
- Análisis de espectro
- Metales, pesado
- Isotipos de inmunoglobulina
- Sulfuros
- Aniones
- Iones
- Electrolitos
- Sulfuro de hidrógeno
- Compuestos de platino
- Elementos de transición
- Docetaxel
- Bevacizumab
- Cetuximab
- Carboplatino
- Inmunoglobulina G
- Cisplatino
- Citrato de 1,2-diaminociclohexanoplatino II
- Manejo de muestras
- Espectroscopía de resonancia magnética
- Disulfides
- Platino
- atezolizumab
- (225) AC-DOTA-C (RGDYK)
Otros números de identificación del estudio
Otros números de identificación del estudio
- NCI-2021-10021
- U10CA180820 (Subvención/contrato del NIH de EE. UU.)
- NCI-2021-10021 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EA3202 (Otro identificador: CTEP)
- EA3202 (Otro identificador: ECOG-ACRIN Cancer Research Group)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .